GO
Loading...

Genentech Warns of Stroke Risk for Blindness Drug Users

Genentech has sent a letter alerting eye doctors to the risk of stroke from Lucentis, its drug for treating age-related macular degeneration, a spokeswoman said.

The letter was a "proactive effort" to advise doctors that an interim analysis of a large 5,000-patient trial shows that 1.2% of patients given a 0.5-milligram dose of the drug suffered a stroke, compared with 0.3% of patients given a 0.3-mg dose, said spokeswoman Dawn Kalmar.

She said the findings mirror those shown in previous trials of Lucentis, which was approved by the U.S. Food and Drug Administration last year.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More*

Don't Miss

U.S. Video

  • CNBC's Tyler Mathisen looks back at the week's top business and financial stories. The markets were closed for Thanksgiving, but did manage to hit new highs. Low oil prices gave consumers more money to spend for Black Friday.

  • Cyber Monday deals on Walmart's website on Dec. 2, 2013.

    CNBC's Tyler Mathisen looks ahead to what are likely to be next week's top stories. The jobs report comes out this week, as do auto sales. And the Rockefeller Center Christmas tree is lit.

  • Following last week's wild energy ride, analysts expect oil prices to continue to drop during the holiday season. CNBC's Patti Domm reports.